Jazz Pharmaceuticals Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 3,627

Employees

  • Stock Symbol
  • JAZZ

Stock Symbol

  • Investments
  • 22

  • Share Price
  • $230.80
  • (As of Friday Closing)

Jazz Pharmaceuticals General Information

Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Waterloo Exchange
  • Waterloo Road
  • Dublin D04 E5W7
  • Ireland
+353 (01)
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • Waterloo Exchange
  • Waterloo Road
  • Dublin D04 E5W7
  • Ireland
+353 (01)

Jazz Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Jazz Pharmaceuticals Stock Performance

As of 20-Nov-2026, Jazz Pharmaceuticals’s stock price is $230.80. Its current market cap is $14.8B with 64.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$230.80 $236.45 $156.95 - $266.38 $14.8B 64.2M 899K $3.37

Jazz Pharmaceuticals Financials Summary

As of 30-Sep-2026, Jazz Pharmaceuticals has a trailing 12-month revenue of $4.72B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 17,238,523 13,712,525 11,028,868 11,951,888
Revenue 4,718,186 4,267,586 4,068,950 3,834,204
EBITDA 1,146,289 263,489 1,368,515 1,226,063
Net Income 205,952 (356,148) 560,120 414,832
Total Assets 11,997,700 11,659,340 12,012,257 11,393,359
Total Debt 5,645,000 5,423,866 6,162,357 5,791,614
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jazz Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jazz Pharmaceuticals‘s full profile, request access.

Request a free trial

Jazz Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorde
Pharmaceuticals
Dublin, Ireland
3,627 As of 2026

Foster City, CA
 

Tarrytown, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Jazz Pharmaceuticals Competitors (25)

One of Jazz Pharmaceuticals’s 25 competitors is Gilead, a Formerly VC-backed company based in Foster City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Formerly VC-backed Foster City, CA
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
Amgen Formerly PE-Backed Thousand Oaks, CA
Harmony Biosciences Holdings Formerly VC-backed Plymouth Meeting, PA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 25 competitors. Get the full list »

Jazz Pharmaceuticals Patents

Jazz Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026210449-A1 Compounds for tmem175 modulation Pending 04-Apr-2025
WO-2026207484-A1 Pharmaceutical compositions and uses thereof for the treatment of pcpg: pheochromocytomas and paragangliomas Pending 28-Mar-2025
US-20260265252-A1 Solid state forms of imipridone derivative Pending 28-May-2024
WO-2025163494-A1 Condensed azines for the treatment of cancer Pending 29-Jan-2024
WO-2025019344-A2 Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof Inactive 14-Jul-2023 A61K31/454
To view Jazz Pharmaceuticals’s complete patent history, request access »

Jazz Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jazz Pharmaceuticals Investments & Acquisitions (22)

Jazz Pharmaceuticals’s most recent deal was a Early Stage VC with Setara Biosciences for . The deal was made on 30-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Setara Biosciences 30-Oct-2026 Early Stage VC Biotechnology
Actio Biosciences 15-Sep-2026 Merger/Acquisition Drug Discovery
Saniona (SAN2355 License) 20-Aug-2025 Corporate Asset Purchase Buildings and Property
Chimerix 21-Apr-2025 Merger/Acquisition Drug Discovery
Redx Pharma (Kirsten Rat Sarcoma Virus Inhibitor Program in Macclesfield, United Kingdom) 07-Feb-2024 Corporate Asset Purchase Drug Discovery
You’re viewing 5 of 22 investments and acquisitions. Get the full list »

Jazz Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.69 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Jazz Pharmaceuticals’s complete esg history, request access »

Jazz Pharmaceuticals Exits (2)

Jazz Pharmaceuticals’s most recent exit was on 12-Jun-2012 from EUSA Pharma (UK). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
EUSA Pharma (UK) 12-Jun-2012 Completed
Prialt 05-May-2010 Merger/Acquisition Completed
To view Jazz Pharmaceuticals’s complete exits history, request access »

Jazz Pharmaceuticals Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
Actio Biosciences San Diego, CA 2021
Jazz Pharmaceuticals Ireland Holdings Dublin, Ireland 2019
Gw Pharma (Germany) Munich, Germany 2018
Gw Pharma (International) Amersfoort, Netherlands 2018
Jazz Financing Uk London, United Kingdom 2011
You’re viewing 5 of 8 affiliates. Get the full list.  »

Jazz Pharmaceuticals FAQs

  • When was Jazz Pharmaceuticals founded?

    Jazz Pharmaceuticals was founded in 2003.

  • Where is Jazz Pharmaceuticals headquartered?

    Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

  • What is the size of Jazz Pharmaceuticals?

    Jazz Pharmaceuticals has 3,627 total employees.

  • What industry is Jazz Pharmaceuticals in?

    Jazz Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Jazz Pharmaceuticals a private or public company?

    Jazz Pharmaceuticals is a Public company.

  • What is Jazz Pharmaceuticals’s stock symbol?

    The ticker symbol for Jazz Pharmaceuticals is JAZZ.

  • What is the current stock price of Jazz Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Jazz Pharmaceuticals is $230.80.

  • What is the current market cap of Jazz Pharmaceuticals?

    The current market capitalization of Jazz Pharmaceuticals is $14.8B.

  • What is Jazz Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Jazz Pharmaceuticals is $4.72B.

  • Who are Jazz Pharmaceuticals’s competitors?

    Gilead, Regeneron Pharmaceuticals, Amgen, Harmony Biosciences Holdings, and Sarepta Therapeutics are some of the 25 competitors of Jazz Pharmaceuticals.

  • What is Jazz Pharmaceuticals’s annual earnings per share (EPS)?

    Jazz Pharmaceuticals’s EPS for 12 months was $3.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process